The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
Search results for: hospital
A New Treatment for Fibromyalgia?
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
Rheumatology Influencers: Dr. Dave Has a Passion for Giving Back
Dr. Amish Dave discusses how his volunteer, advocacy & public outreach work stem from his greater commitment to community & helping others.
Case Reports: Mimics of Polyarteritis Nodosa
When polyarteritis nodosa isn’t PAN: Two cases of mimics, segmental arterial mediolysis (SAM) & vascular Ehlers-Danlos syndrome (vEDS), are explored.
AMA State Advocacy Roundtable Addresses Pressing Policy Challenges
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
Celebrating Interdisciplinary Collaboration: Pathways to Success
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
Sjögren’s Dry Eye Requires Collaboration Among Eye Doctors, Rheumatologists
Sjögren’s dry eye requires collaboration between rheumatologists and ophthalmologists for optimal patient management and treatment of this quality-of-life issue.
Dazodalibep for Sjögren’s Disease
St.Clair et al. found that patients with Sjögren’s disease treated with dazodalibep experienced greater improvement in key symptoms of dryness, fatigue & pain than patients who received placebo.
New FDA Label Requirements for Opioids
After reviewing data from post-marketing observational studies, the FDA has issued new labeling requirements for opioids with the goal of emphasizing and explaining the risks associated with long-term use.
Promising Phase 2 Results for Efgartigimod alfa-fcab in Adults with Primary Sjögren’s Disease
A study from Peene et al. found that patients with primary Sjögren’s disease experienced significant improvements in systemic disease activity and symptoms when treated with intravenous efgartigimod alfa-fcab.
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 328
- Next Page »